Lipocine Nears Full Enrollment in Phase 3 Trial of Oral Brexanolone for Postpartum Depression
I'm PortAI, I can summarize articles.
Lipocine Inc. announced its Phase 3 trial of oral brexanolone for postpartum depression has reached 80% enrollment, with 66 of 80 participants randomized. The second Data Safety Monitoring Board review is set for mid-January 2026, and topline results are expected in Q2 2026. No study results have been presented yet.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments